US5437864A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
Assignee: Scripps Research Institute
•
Filing: 1992-11-16
•
Granted: 1995-08-01
•
Expires: 2012-11-16
Abstract
Abstract This invention provides a method of inhibiting coagulation in extracorporeal circulation in a subject, comprising administration of a therapeutically effective amount of a monoclonal antibody which inhibits the ability of tissue factor to bind to factor VII/VIIa. The method prevents complex formation between tissue factor and factor VII/VIIa and thus inhibits coagulation of blood in extracorporeal procedures such as cardiopulmonary bypass and other shunt procedures. Anti-tissue factor monoclonal antibodies produced by hybridoma cell lines TFS-5G9 or TF9-6B4 may be used in the claimed methods.
Inventors
- 👤 Thomas S. Edgington
- 👤 Robert W. Colman
- 👤 Janos Kappelmayer
- 👤 L. Henry Edmunds, Jr.
- 👤 Alvise Bernabei
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 02:17
CPC Classifications
C; C07; C07H; C07H21/00; A; A61; A61P; A61P7/00; A61P7/02; C07K; C07K14/00; C07K14/435; C07K14/745; C07K16/00; C07K16/18; C07K16/36; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/86; A61K; A61K39/00; A61K2039/505; A61K38/00; G01N2333/00; G01N2333/435; G01N2333/745
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
57 words
A method of inhibiting coagulation in an extracorporeal circulation procedure used on a subject extracorporeally, comprising (1) removing blood from a subject and (2) administering to the blood a therapeutically effective amount of a monoclonal antibody which inhibits binding of tissue factor to factor VII/VIIa so that the activity of tissue factor is neutralized in the vasculature.
Claim 2
Independent Claim
57 words
A method of inhibiting coagulation in an extracorporeal circulation procedure used on a subject extracorporeally, comprising (1) removing blood from a subject and (2) administering to the blood a therapeutically effective amount of a monoclonal antibody which inhibits binding of tissue factor to factor VII/VIIa so that the activity of tissue factor is neutralized in the vasculature.
Claim 3
Dependent Claim
15 words
The method of claim 1, wherein the extracorporeal circulation procedure is a cardiopulmonary bypass procedure.
Claim 4
Dependent Claim
11 words
The method of claim 1, wherein the subject is a mammal.
Claim 5
Dependent Claim
11 words
The method of claim 1, wherein the subject is a primate.
Claim 6
Dependent Claim
11 words
The method of claim 3, wherein, the mammal is a human.
Claim 7
Dependent Claim
30 words
The method of claim 1, wherein the monoclonal has the specificity of a monoclonal selected from the group consisting of monoclonal antibodies produced by hybridoma cell lines TF8-5G9, and TF9-6B4.
Claim 8
Dependent Claim
26 words
The method of claim 6, wherein the monoclonal antibody is selected from the group consisting of monoclonal antibodies produced by hybridoma cell lines TF8-5G9, and TF9-6B4.
Claim 9
Dependent Claim
14 words
The method of claim 1, wherein the administration of the monoclonal antibodies is intravenous.
Claim 10
Dependent Claim
17 words
The method of claim 1 wherein said monoclonal antibody is administered to a particular patient only once.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-07-31 | 1999-01-30 | 1999-08-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-07-31 | 2003-01-30 | 2003-08-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-07-31 | 2007-01-30 | 2007-08-01 | $7700.00 | Window Closed / Lapsed |